Circulating subsets and CD4CD25 regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy

Autoimmunity

Volumn 42, Issue 8, 2009, Pages 667-677

  Sanvito, Lara ^a,b   Makowska, Anna ^a   Gregson, Norman ^a   Nemni, Raffaello ^b   Hughes, Richard A C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

CIDP; Circulating subsets; Myelin proteins; Neuropathy; Regulatory T cells

Indexed keywords

IMMUNOGLOBULIN; MYELIN PROTEIN; TRANSCRIPTION FACTOR FOXP3; CD3 ANTIGEN; PEPTIDE FRAGMENT;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER T CELL; POLYCLONAL ACTIVATION; POLYRADICULONEUROPATHY; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; ANTIGEN PRESENTING CELL; BLOOD; CYTOLOGY; IMMUNOLOGY; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; NATURAL KILLER CELL;

ADULT; AGED; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD3; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MONOCYTES; MYELIN PROTEINS; NATURAL KILLER T-CELLS; PEPTIDE FRAGMENTS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 70449377977     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903140907     Document Type: Article

References (52)

1. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352(13):1343-1356.
2. Hughes RAC, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Sys 2006;11(1):30-46.
3. Mäurer M, Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002;15(5):617-622.
4. Allen D, Giannopoulos K, Gray I, Gregson N, Makowska A, Pritchard J, Hughes RAC. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Sys 2005;10(2):174-180.
5. Csurhes PA, Sullivan AA, Green K, Pender MP, McCombe PA. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psych 2005;76(10):1431-1439.
6. Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psych 2007;78(4):419-422.
7. Sanvito L, Makowska A, Mahdi-Rogers M, Hadden RD, Peakman M, Gregson N, Nemni R, Hughes RA. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2009;80(3):333-338.
8. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103(15):5941- 5946.
9. De Jager PL, Rossin E, Pyne S, Tamayo P, Ottoboni L, Viglietta V, Weiner M, Soler D, Izmailova E, Faron-Yowe L, O'Brien C, Freeman S, Granados S, Parker A, Roubenoff R, Mesirov JP, Khoury SJ, Hafler DA, Weiner HL. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008;131(7): 1701-1711.
10. Hostmann A, Jacobi AM, Mei H, Hiepe F, Dorner T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 2008;17(12):1064-1069.
11. Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007;28(3):121-126.
12. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005;105(11):4390-4398.
13. Seidi OA, Semra YK, Sharief MK. Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J Neuroimmunol 2002;133(1):205-210.
14. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dorner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165(10):5970-5979.
15. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401(6754): 708-712.
16. + T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J Neuroimmunol 2007;183(1-2):168-174.
17. + effector memory T cells in Wegener's granulomatosis. Kidney Int 2006;70(5): 938-947.
18. + T cells. Immunology 2004;112(2):274-289.
19. Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, Valle MT, Pedemonte E, Noonan D, Albini A, Bernardi G, Mancardi GL, Battistini L, Uccelli A. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leuk Biol 2003; 73(5):584-590.
20. Trebst C, Brunhorn K, Lindner M, Windhagen A, Stangel M. Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins. Eur J Neurol 2006;13(12):1359-1363.
21. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008;9(5): 503-510.
22. Créange A, Gregson NA, Hughes RAC. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte Fc-gamma RII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003;135(1-2):91-95.
23. Mata S, Corzani S, Biagiotti R, Piacentini S, Siracusa G, Giudizi MG, Mastio MD, Borsini W, Taiuti R, Vultaggio A, Sorbi S, Maggi E. Influence of impaired T- and B-cell compartments on efficacy of IVIg in dysimmune neuropathies. Eur J Neurol 2007;14(10):1147-1153.
24. Dahle C, Vrethem M, Ernerudh J. T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain-Barré syndrome. J Neuroimmunol 1994;53(2): 219-225.
25. + cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci 2008;15(9):1031-1035.
26. Sindern E, Oreja-Guevara C, Raulf-Heimsoth M, Baur X, Malin JP. A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barré syndrome. J Neurol Sci 1997;151(1):29-34.
27. Yoshii F, Shinohara Y. Lymphocyte subset proportions in Guillain-Barré syndrome patients treated with plasmapheresis. Eur Neurol 2000;44(3):162-167.
28. + regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol 2007;192(1-2): 206-214.
29. + regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Sys 2008;13(1):54-63.
30. + cell populations in Guillain-Barré syndrome. J Neuroimmunol 2007; 183(1-2):232-238.
31. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004;22(1):531-562. (Pubitemid 38680433)
32. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299(5609):1057-1061.
33. + regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007;319(1-2):41-52.
34. Baecher-AllanC,HaflerDA.Human regulatoryTcells and their role in autoimmune disease. Immunol Rev 2006;212:203-216.
35. +CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178(4): 2579-2588.
36. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199(7): 971-979.
37. Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RDM, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13(4):326-332.
38. Makowska A, Pritchard J, Sanvito L, Gregson N, Peakman M, Hayday A, Hughes R. Immune responses to myelin proteins in Guillain-Barré syndrome. J Neurol Neurosurg Psych 2008; 79(6):664-671.
39. +CD25high regulatory cells in human peripheral blood. J Immunol 2001;167(3):1245-1253.
40. Rizzuto N, Morbin M, Cavallaro T, Ferrari S, Fallahi M, Rizzuto GS. Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neuropathol 1998;96(6):603-609.
41. +CD572 Natural killer cells in multifocal motor neuropathy. Eur Neurol 2005;53(2):64-67.
42. Yoshii F, Shihohara Y. Natural killer cells in patients with Guillain-Barré syndrome. J Neurol Sci 1998;157(2):175-178.
43. Vrethem M, Dahle C, Ekerfeldt C, Nilsson J, Ekstedt B, Ernerudh J. Abnormalities in T-lymphocyte populations in blood from patients with demyelinating polyneuropathy associated with monoclonal gammopathy. J Neurol Sci 1994; 122(2):171-178.
44. Illes Z, Kondo T, Newcombe J, Oka N, TabiraT, Yamamura T. Differential expression of NK T cell Valpha24-JalphaQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000;164(8):4375-4381.
45. Segal BM. The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol 2007;191(1-2):2-7.
46. + T-cells from patients with type 1 diabetes. Diabetes 2005; 54(1):92-99.
47. + regulatory T-cell function and Foxp3 expression. J Neurosci Res 2006;83(8): 1432-1446.
48. Crispin JC, Martinez A, Cocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21(3):273-276. (Pubitemid 37410115)
49. De Luca G, Lugaresi A, Iarlori C, Marzoli F, Uncini A, Gambi D. Interferon- beta normalizes suppressor cell function in dysimmune neuropathies. J Neuroimmunol 1998;82(1):1-4.
50. De Luca G, Lugaresi A, Iarlori C, Marzoli F, Di Iorio A, GambiD, Uncini A. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1999;95(1-2): 190-194.
51. Susuki K, Rasband MN. Molecular mechanisms of node of Ranvier formation. Curr Opin Cell Biol 2008;20(6): 616-623.
52. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 2006;77(8):973-976.